STOCK TITAN

Royalty Pharma to Announce Third Quarter 2022 Financial Results on November 8, 2022

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Royalty Pharma plc (RPRX) will announce its third quarter 2022 financial results on November 8, 2022, before U.S. markets open. A conference call will follow at 8:00 a.m. Eastern Time, accessible via the company's website. Royalty Pharma specializes in acquiring biopharmaceutical royalties and funding innovation in the sector, holding royalties on over 35 commercial products. These include notable therapies like Vertex's Trikafta and Biogen's Tysabri. For further details, visit the company's investors page.

Positive
  • None.
Negative
  • None.

NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Conference Call Information

Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Biohaven and Pfizer’s Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s Trodelvy, and 12 development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com


FAQ

When will Royalty Pharma report its third quarter 2022 financial results?

Royalty Pharma will report its third quarter 2022 financial results on November 8, 2022.

What time is the Royalty Pharma conference call for Q3 2022 results?

The conference call will take place at 8:00 a.m. Eastern Time on November 8, 2022.

Where can I find the webcast for Royalty Pharma’s Q3 2022 results?

The webcast can be found on the Investors page of Royalty Pharma's website.

What types of products does Royalty Pharma hold royalties on?

Royalty Pharma holds royalties on over 35 commercial products, including Vertex's Trikafta and AbbVie's Imbruvica.

Royalty Pharma plc

NASDAQ:RPRX

RPRX Rankings

RPRX Latest News

RPRX Stock Data

10.96B
380.91M
13.17%
72.78%
3.3%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK